about
Cerebrospinal fluid biomarkers of Alzheimer’s diseaseFluid Biomarkers in Clinical Trials of Alzheimer's Disease TherapeuticsThe potential of pathological protein fragmentation in blood-based biomarker development for dementia - with emphasis on Alzheimer's diseaseNew pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugsInsight of brain degenerative protein modifications in the pathology of neurodegeneration and dementia by proteomic profilingAdvances in MRI biomarkers for the diagnosis of Alzheimer's disease.Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease.CSF and Brain Indices of Insulin Resistance, Oxidative Stress and Neuro-Inflammation in Early versus Late Alzheimer's DiseaseThe future of blood-based biomarkers for Alzheimer's disease.Evaluation of the performance of novel Aβ isoforms as theragnostic markers in Alzheimer's disease: from the cell to the patient.The preclinical Alzheimer cognitive composite: measuring amyloid-related declineAlzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI.Enrichment and stratification for predementia Alzheimer disease clinical trials.An enzyme-generated fragment of tau measured in serum shows an inverse correlation to cognitive function.Cerebrospinal fluid β-amyloid1-42 levels in the differential diagnosis of Alzheimer's disease--systematic review and meta-analysis.A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysisSynthesis, characterization, and preclinical validation of a PET radiopharmaceutical for interrogating Aβ (β-amyloid) plaques in Alzheimer's diseaseEnvironmental factors preceding aβ40 monomer to oligomers and the detection of oligomers in Alzheimer's disease patient serumMolecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development.Will posttranslational modifications of brain proteins provide novel serological markers for dementias?Estimation of Tau and Phosphorylated Tau181 in Serum of Alzheimer's Disease and Mild Cognitive Impairment Patients.Label-free quantitative LC-MS proteomics of Alzheimer's disease and normally aged human brains.Measuring clinical progression in MCI and pre-MCI populations: enrichment and optimizing clinical outcomes over timeDouble-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease.Muscle-directed anti-Aβ single-chain antibody delivery via AAV1 reduces cerebral Aβ load in an Alzheimer's disease mouse model.Measurement of Blood Thiamine Metabolites for Alzheimer's Disease Diagnosis.Role of the Transforming-Growth-Factor-β1 Gene in Late-Onset Alzheimer's Disease: Implications for the TreatmentDetection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers.Distinct prion-like strains of amyloid beta implicated in phenotypic diversity of Alzheimer's disease.Fluselenamyl: A Novel Benzoselenazole Derivative for PET Detection of Amyloid Plaques (Aβ) in Alzheimer's Disease.New treatment strategies for Alzheimer's disease: is there a hope?Serum microRNA miR-501-3p as a potential biomarker related to the progression of Alzheimer's disease.Can Salivary Acetylcholinesterase be a Diagnostic Biomarker for Alzheimer?Brain rust: recent discoveries on the role of oxidative stress in neurodegenerative diseases.Biomarker-driven therapeutic management of Alzheimer's disease: establishing the foundations.Implications of prion adaptation and evolution paradigm for human neurodegenerative diseases.Study on Analysis of Peripheral Biomarkers for Alzheimer's Disease Diagnosis.Routine lumbar puncture for the early diagnosis of Alzheimer's disease. Is it safe?Metabolomic-guided discovery of Alzheimer's disease biomarkers from body fluid.Alzheimer's disease biomarkers in animal models: closing the translational gap.
P2860
Q22252572-B6C71007-CF35-423A-A73E-7EC5765FD1B2Q26784569-A16B34F6-4F2C-47AF-9CC8-BCBB39CADBCBQ26853347-C17C345D-25AC-4DE2-BE97-F39928BC640DQ26866006-EABD4D98-DE8B-4463-AD6C-D2844717E38FQ28076999-E15EF461-1A1A-4AE3-842E-FC280C39A749Q30870223-C09E5CF2-A684-4EFC-B9EB-1C5F67134278Q33745617-3C08A534-370B-41E2-BB16-6FB9AD4C57B6Q33896118-8ABC9C73-209F-4058-AF9B-C1ED00C75E1BQ34026317-C46FAAF6-CC87-4E0E-A418-154B59875C82Q34149524-22C92AE6-CDE6-4548-9449-355C70B49E78Q34422469-1D96943A-B763-47B1-94C1-1586E1B5D2FCQ34450243-B53D699B-941A-4916-9087-C1D046D9C7AFQ34452239-E08B10CC-D98A-44A3-B92B-D4C7B384CAEAQ34746609-76FC2F23-0124-4B14-8641-B0EFC61E5EF9Q35117772-7B43304B-9580-4B8B-915B-F1B8BE92E48FQ35158547-BA654A97-BBDC-4047-A897-9672BB8C39BFQ35772537-EFBA3F10-F946-4090-91C6-276511E83EB6Q35837396-642B9FDC-9243-4073-83A2-5FE997CB5E8AQ35840623-D39A706E-80E0-4F6C-9AF1-1C359E885D80Q36072517-9DA31434-6866-4017-A0C4-021CBA602F55Q36086092-3CFAA8F8-C3BB-48F3-A73D-E31571FD6232Q36243522-EB1898E4-21F9-4C18-A0B0-259C860F0FC8Q36424833-D05EF05B-BCC5-4D83-A6B9-8A208EB12A5AQ36517542-AAEABF32-3FEC-4C93-B6FA-613135935D11Q36532822-9FFA3E7A-13BF-4E2A-A7F7-609B1033E89CQ36538775-9C7E1D9F-AA6B-48A1-9C97-BDE5F2CF6E32Q36798886-00632DC2-11CC-4075-9462-5D4B17D61161Q36934163-FCF48C08-B464-4F59-9597-027AEF74E963Q37167860-C08E34D6-28F9-4FFC-8EF7-0E9B0D15D058Q37386143-5527000A-A678-4C68-9272-71FC42B8ADBCQ37403383-7E646AE7-C195-4C48-BCF1-F8DFD3A4F531Q37615645-8A316F34-A83D-4276-A0FE-363F0F4918CBQ37663763-93C2BC0B-FF57-4B80-86BB-2F37EE929E20Q38009974-5B7E00FC-FCF0-424B-A605-7316F82F93FFQ38150708-D9DB9113-C822-421A-B1A4-E7A3BE7598C9Q38176721-828645AC-5C17-40A7-ADF0-F39330C6423DQ38647864-BB051FAA-49B9-4BDA-83D5-5B4BD0AD7666Q38779363-81DC1BC0-4B34-4280-A795-DBF5D7905EE8Q39181900-46363CBB-221D-49E1-8706-6C8EC62AEC7CQ41822193-7C1BF2F0-4128-4DFE-AD70-E131ED137BC3
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Biomarkers in Alzheimer's disease drug development.
@en
Biomarkers in Alzheimer's disease drug development.
@nl
type
label
Biomarkers in Alzheimer's disease drug development.
@en
Biomarkers in Alzheimer's disease drug development.
@nl
prefLabel
Biomarkers in Alzheimer's disease drug development.
@en
Biomarkers in Alzheimer's disease drug development.
@nl
P1476
Biomarkers in Alzheimer's disease drug development.
@en
P304
P356
10.1016/J.JALZ.2010.06.004
P577
2011-05-06T00:00:00Z